On Monday, October 14, shares of Longboard Pharmaceuticals, which is developing medicines for neurological diseases, surged more than 50% after the company announced a deal to be acquired by its Danish peer Lundbeck. The transaction is valued at $2.6 billion, almost 14% above Longboard’s current market capitalization. Details On Monday,…